New pill aims to tame rare kidney disorder that makes patients drink constantly
NCT ID NCT07525960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a daily capsule called NDI-5001 in 24 adult men with a rare inherited kidney condition (X-linked congenital nephrogenic diabetes insipidus) that causes extreme thirst and frequent urination. The study's main goal is to check the drug's safety and how it affects urine output and concentration. If it works, it could offer a new way to manage this lifelong condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NDI-5001 (capsule)
What this could lead to
If successful, this could point toward a daily pill to reduce excessive urination and improve water balance in people with X-linked NDI.
What could go wrong
This is an early Phase 1b trial with only 24 participants, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED CONGENITAL NEPHROGENIC DIABETES INSIPIDUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••